West Pharmaceutical Services (United States)
WST
$349.42
+0.94%
West Pharmaceutical Services, Inc. is a leading global manufacturer of packaging components and delivery systems for the pharmaceutical, biotechnology, and generic drug industries, including elastomer stoppers, seals, plungers, and auto-injectors. The company holds a dominant market position as a critical supplier to injectable drug manufacturers, with a strong competitive moat built on regulatory expertise and customer relationships. Currently, the stock is in the spotlight due to robust growth driven by the surging demand for GLP-1 receptor agonists, which has led to an earnings beat and raised annual guidance, fueling investor optimism about sustained expansion. The narrative centers on whether the company can capitalize on this high-growth therapeutic area while managing capacity and margin pressures.…
WST
West Pharmaceutical Services (United States)
$349.42
Related headlines
Investment Opinion: Should I buy WST Today?
Based on the analysis, WST is rated a Buy. The company's accelerating revenue growth (21% YoY), expanding margins, and strong analyst consensus (Strong Buy, average target $404.73) support a positive outlook. The core thesis is that WST is a key beneficiary of the GLP-1 boom, with a dominant market position that should drive sustained growth.
Sign up to view all
WST 12-Month Price Forecast
The AI assessment is bullish, driven by WST's strong growth fundamentals and market position. The company's revenue growth is well above industry norms, and margins are expanding, indicating operational excellence. However, the high valuation and dependence on GLP-1 demand introduce uncertainty, warranting a medium confidence. If growth continues to accelerate and capacity expands, the stock could outperform; conversely, any signs of slowdown would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $404.73 and implied upside of +15.8% versus the current price.
Average Target
$404.73
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$340 - $459
Analyst target range
Analyst coverage is robust with 15 analysts, and the consensus recommendation is a Strong Buy, with a mean rating of 1.44 (where 1 is Strong Buy). The average target price is $404.73, implying an upside of 16.1% from the current price of $348.60. The distribution shows 14 analysts with Buy or Overweight ratings and 1 with Hold, indicating strong bullish sentiment. The target range spans from $340.00 to $459.00, with the low target representing a 2.5% downside and the high target implying a 31.7% upside. The wide spread of $119 suggests significant uncertainty about the growth trajectory, but the recent upgrades from Barclays (Overweight) and Keybanc (Overweight) in June and July 2026 indicate positive momentum in analyst sentiment. The high target likely assumes continued GLP-1-driven growth and margin expansion, while the low target may reflect concerns about capacity constraints or competitive pressures.
Bulls vs Bears: WST Investment Factors
WST presents a compelling growth story driven by GLP-1 tailwinds, with accelerating revenue, expanding margins, and strong analyst support. However, the elevated valuation (PE 40.3x vs. industry 22x) and heavy reliance on GLP-1 demand introduce significant risk. The bull case is currently stronger, given the company's dominant market position and proven execution, but the key tension is whether growth can sustain the premium valuation. If GLP-1 growth decelerates or capacity constraints emerge, the stock could face multiple compression. Overall, the evidence leans bullish, but investors should monitor GLP-1 trends and capacity expansion closely.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue surged 21.0% YoY to $844.9M, up from 7.6% growth in Q1 2025, driven by GLP-1 drug delivery demand. This acceleration indicates strong market tailwinds and successful capacity expansion.
- Margin Expansion and Operating Leverage: Gross margin improved to 35.1% from 33.3% YoY, and operating margin expanded to 21.0% from 18.4%. This demonstrates the company's ability to scale profitably, with net income up 54.5% YoY to $138.8M.
- Strong Analyst Conviction: With 15 analysts, consensus is Strong Buy (mean rating 1.44), and average target price of $404.73 implies 16.1% upside. Recent upgrades from Barclays and KeyBanc in June-July 2026 reinforce positive sentiment.
- Robust Balance Sheet and Cash Flow: Debt-to-equity is a conservative 0.13, current ratio is 3.02, and TTM free cash flow is $458M. This financial strength supports continued investment in capacity and shareholder returns.
Bearish
- Elevated Valuation with High Expectations: Trailing PE is 40.3x, 83% above the industry average of 22x. The PEG ratio of 34.0x suggests the market is pricing in aggressive growth, leaving little room for disappointment.
- Dependence on GLP-1 Drug Demand: Growth is heavily tied to the GLP-1 market, which could face pricing pressures, competition, or regulatory changes. Any slowdown in GLP-1 adoption would directly impact WST's revenue growth.
- Potential Capacity Constraints: The company is expanding to meet demand, but if capacity additions lag or face operational issues, it could limit growth and margin expansion. Q1 2026 operating cash flow was impacted by a $297.6M stock repurchase, reducing liquidity.
- Recent Price Volatility: The stock dropped 7.6% on July 24, 2026, from $355.48 to $328.20, indicating sensitivity to market news. With a beta of 1.14, WST is more volatile than the market, which could amplify downside in a sell-off.
WST Technical Analysis
West Pharmaceutical's stock is in a strong uptrend, with a 1-year price change of +46.9%, significantly outperforming the S&P 500's +21.5% over the same period. The current price of $348.60 sits at 90.3% of its 52-week range (low $223.83, high $386.00), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. The stock has recovered sharply from its 52-week low, with a 6-month gain of 40.0%, and is within 9.7% of its all-time high, suggesting a bullish trend with strong investor conviction.
Beta
1.14
1.14x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$224-$386
Price range past year
Annual Return
+41.9%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | -2.7% | +2.9% |
| 3m | +15.4% | +5.0% |
| 6m | +39.5% | +13.9% |
| 1y | +41.9% | +20.4% |
| ytd | +26.4% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
Revenue growth is accelerating, with Q1 2026 revenue of $844.9 million up 21.0% year-over-year, compared to 7.6% growth in Q1 2025. The company's proprietary products segment, which accounts for approximately 80% of revenue, is driving this growth, fueled by demand for GLP-1 drug delivery systems. Net income for Q1 2026 was $138.8 million, up from $89.8 million in the prior year quarter, reflecting a net margin of 16.4% versus 12.9% a year ago. Gross margin improved to 35.1% from 33.3% in Q1 2025, while operating margin expanded to 21.0% from 18.4%, indicating strong operating leverage. The balance sheet remains conservative with a debt-to-equity ratio of 0.13 and a current ratio of 3.02, providing ample liquidity. Free cash flow for the trailing twelve months was $458 million, and the company generated $89.9 million in operating cash flow in Q1 2026, though this was impacted by a $297.6 million stock repurchase, which reduced cash balances. ROE stands at 15.5%, reflecting efficient capital allocation, and the company's payout ratio of 12.4% supports a modest dividend yield of 0.31%.
Quarterly Revenue
$844900000.0B
2026-03
Revenue YoY Growth
+21.0%
YoY Comparison
Gross Margin
35.1%
Latest Quarter
Free Cash Flow
$458000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Given positive net income, the PE ratio is the primary valuation metric. The trailing PE is 40.3x, while the forward PE is 35.0x, indicating the market expects earnings growth of approximately 15% over the next year. This forward discount suggests optimism about continued growth, but the PEG ratio of 34.0x is elevated, implying that the stock is priced for high growth expectations. Compared to the industry average PE of 22x (based on available data), WST trades at a 83% premium, reflecting its superior growth profile and market position. The premium is justified by the company's 21% revenue growth and 16.4% net margin, which are well above industry norms. Historically, the stock's PE has ranged from 30x to 63x over the past five years, with the current 40.3x sitting near the middle of that range, suggesting the market is pricing in sustained growth but not at extreme levels. The PS ratio of 6.5x is also above the historical average of 30x, but this is distorted by the recent price surge.
PE
40.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's high valuation, which leaves little margin for error. With a trailing PE of 40.3x and forward PE of 35.0x, any earnings miss could trigger a sharp de-rating. The PEG ratio of 34.0x is extremely elevated, indicating that the market expects near-perfect execution. Additionally, while the balance sheet is conservative (debt-to-equity 0.13), the company's aggressive share repurchases ($297.6M in Q1 2026) could strain liquidity if cash flows weaken. Revenue concentration in the proprietary products segment (~80%) and reliance on GLP-1 drugs expose the company to demand shocks in that therapeutic area.
FAQ
The key risks are: 1) Dependence on GLP-1 drug demand, which could slow due to competition or regulatory changes; 2) Valuation risk, as the high PE could compress if growth disappoints; 3) Operational risks, including capacity constraints and margin pressure; 4) Market risk, with a beta of 1.14 indicating higher volatility. The most severe risk is a GLP-1 slowdown, which could lead to a -35% decline to the 52-week low. Investors should monitor these factors closely.
The 12-month forecast is positive, with a base case target of $404.73 (16.1% upside) and a bull case target of $459 (31.7% upside). The bear case target is $340 (2.5% downside), but the probability-weighted expected return is approximately +12%. The most likely scenario is the base case, which assumes continued GLP-1-driven growth at a sustainable pace. Analysts are bullish, with a Strong Buy consensus, but the stock's performance will depend on execution and market conditions.
WST trades at a trailing PE of 40.3x, which is 83% above the industry average of 22x, indicating a premium valuation. However, this premium is justified by its superior growth (21% revenue growth vs. industry ~7%) and profitability (net margin 16.4%). The forward PE of 35.0x suggests the market expects continued earnings growth. Historically, the stock's PE has ranged from 30x to 63x, so the current level is within its historical range. Overall, WST is fairly valued relative to its growth potential, but it is not a bargain.
WST is a good buy for growth-oriented investors with a long-term horizon, given its strong revenue growth (21% YoY) and margin expansion. The average analyst target of $404.73 implies 16.1% upside, and the consensus is Strong Buy. However, the stock is not cheap, with a trailing PE of 40.3x, so it is sensitive to any growth disappointment. If you believe in the long-term GLP-1 trend, WST is a compelling investment, but it's essential to size positions appropriately given the volatility.
WST is better suited for long-term investment, given its growth trajectory and market position. The company is in a high-growth phase, with revenue growing 21% YoY, and it benefits from secular trends in injectable drugs. Short-term trading is possible due to volatility (beta 1.14), but the stock's valuation requires a longer horizon to realize gains. A minimum holding period of 3-5 years is recommended to ride out market fluctuations and allow the GLP-1 opportunity to fully materialize.